Strategies For Ensuring Virus Bank Manufacturing Success

Creating high-quality virus seed stocks is critical in viral vector production for gene therapies and vaccine manufacturing. Typically, these stocks are established when the virus or construct is selected for the anticipated product. The terminology used to describe virus banks parallels that of cell banks, comprising research, master, and working designations. Research virus banks are utilized to develop master virus seed stocks, which are fully characterized to support the product pipeline. The working virus seed stock is then produced from vials of the master virus seed stock bank and serves as the material for routine clinical batch production.

Here, we outline the processes and best practices applied at the MilliporeSigma good manufacturing practice (GMP) facility in Glasgow, Scotland to optimize the production of working virus seed stocks (WVSS) and master virus seed stocks (MVSS). Explore relevant regulatory and testing requirements as well as key factors for ensuring the successful manufacture of virus banks.